Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00830154 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering

A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.

Completed
Registry status
Phase 2
Development phase
321
Enrollment target

NCT00830154: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.

NCT00830154 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 321 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00830154, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.

COMPLETED
Registry status
Phase 2
Development phase
321 participants
Enrollment target

Study Summary

A multicenter, randomized, 3 arm, placebo-controlled clinical trial to assess the efficacy, safety and tolerability of pagoclone for adults with stuttering.

Interventions

  • OTHER placebo
  • DRUG pagoclone

Trial Details

FieldValue
Enrollment Target 321 participants
Start Date 2009-02
Est. Completion 2011-01
Phase Phase 2

What the Registry Record Tells You About NCT00830154

The ClinicalTrials.gov registry entry for NCT00830154 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00830154 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00830154 about?

NCT00830154 is a clinical study titled "A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering". A multicenter, randomized, 3 arm, placebo-controlled clinical trial to assess the efficacy, safety and tolerability of pagoclone for adults with stuttering.

What is the current status of trial NCT00830154?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 321 participants. The study started on 2009-02. Estimated completion is 2011-01.

What interventions are being tested in trial NCT00830154?

The interventions under investigation include: placebo (OTHER), pagoclone (DRUG).

Who is sponsoring clinical trial NCT00830154?

This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.